Profile data is unavailable for this security.
About the company
Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.
- Revenue in EUR (TTM)0.00
- Net income in EUR279.84k
- Incorporated2008
- Employees10.00
- LocationHerantis Pharma OyjBertel Jungin aukio 1ESPOO 02600FinlandFIN
- Phone+358 92221195
- Fax+358 196114211
- Websitehttps://herantis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corline Biomedical AB | 2.15m | -155.34k | 20.13m | 13.00 | -- | 2.51 | -- | 9.36 | -0.0841 | -0.0841 | 1.16 | 4.34 | 0.248 | -- | 10.92 | 1,925,385.00 | -1.79 | -5.71 | -1.92 | -6.24 | 113.38 | 128.60 | -7.22 | -38.46 | -- | -89.40 | -- | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| SynAct Pharma AB | 0.00 | -18.54m | 20.49m | 5.00 | -- | 1.35 | -- | -- | -6.54 | -6.54 | 0.00 | 4.95 | 0.00 | -- | -- | 0.00 | -116.46 | -125.17 | -130.53 | -151.70 | -- | -- | -- | -- | -- | -- | 0.0036 | -- | -- | -- | -117.54 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -3.19m | 20.97m | -- | -- | 13.86 | -- | -- | -4.05 | -4.05 | 0.00 | 0.4726 | 0.00 | -- | -- | -- | -159.35 | -127.85 | -206.31 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | 0.2781 | -- | -- | -- | 2.38 | -- | -- | -- |
| Thor Medical ASA | 0.00 | -473.67k | 21.21m | 1.00 | -- | 0.9155 | -- | -- | -0.0318 | -0.152 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -2.52 | -79.17 | -2.84 | -113.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Arctic Bioscience AS | 2.87m | -3.88m | 21.50m | 20.00 | -- | 0.9763 | -- | 7.48 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Lumito AB (publ) | 0.00 | -2.22m | 23.41m | 15.00 | -- | 2.64 | -- | -- | -0.125 | -0.125 | 0.00 | 0.4997 | 0.00 | -- | -- | 0.00 | -19.98 | -20.77 | -22.14 | -22.38 | -- | -- | -- | -- | 1.42 | -- | 0.0884 | -- | -- | -- | 4.56 | -- | -- | -- |
| Lytix Biopharma AS | 339.94k | -7.49m | 23.69m | -- | -- | 4.35 | -- | 69.70 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.037 | -- | 0.4091 | -- | -81.63 | -57.34 | -94.30 | -66.09 | -- | -- | -2,203.36 | -4,665.04 | -- | -- | -- | -- | 183.25 | 63.94 | -57.01 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -2.28m | 23.93m | 7.00 | -- | 6.15 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Ultimovacs ASA | 0.00 | -16.12m | 24.50m | 27.00 | -- | 1.03 | -- | -- | -5.50 | -5.50 | 0.00 | 8.12 | 0.00 | -- | -- | 0.00 | -44.08 | -28.80 | -50.02 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0131 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Aqua Bio Technology ASA | 1.15m | -128.01k | 24.75m | 2.00 | -- | 13.51 | 335.67 | 21.50 | -0.1599 | -0.1599 | 0.4938 | 0.3673 | 0.3079 | 0.6548 | 9.01 | -- | -3.42 | -80.72 | -6.75 | -125.29 | 66.69 | 5.57 | -11.12 | -965.98 | 0.1044 | 0.611 | 0.7538 | -- | 349.88 | 42.04 | 1.97 | -- | -- | -- |
| Medivir AB | 655.83k | -7.67m | 25.80m | 10.00 | -- | 1.29 | -- | 39.34 | -1.46 | -1.46 | 0.1127 | 2.09 | 0.0292 | -- | 2.73 | 763,300.00 | -34.22 | -28.91 | -41.03 | -34.77 | -802.20 | -467.42 | -1,170.21 | -675.96 | -- | -- | 0.0585 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Intervacc AB | 688.65k | -8.84m | 27.23m | 15.00 | -- | 1.33 | -- | 39.55 | -1.47 | -1.47 | 0.1167 | 3.14 | 0.0306 | 3.08 | 1.72 | 534,333.30 | -39.21 | -17.62 | -42.12 | -18.77 | -628.60 | -243.59 | -1,283.24 | -626.90 | 4.38 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Magle Chemoswed Holding AB | 14.64m | 1.05m | 28.02m | 78.00 | 26.80 | 2.06 | 12.90 | 1.91 | 1.13 | 1.13 | 15.78 | 14.65 | 0.6483 | 0.4955 | 10.28 | 2,185,128.00 | 4.63 | 2.52 | 6.01 | 3.52 | 90.31 | 85.67 | 7.14 | 3.92 | 0.6432 | 6.16 | 0.2760 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Herantis Pharma Oyj | 0.00 | 279.84k | 29.23m | 10.00 | 115.35 | 6.19 | 104.46 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| INIFY Laboratories AB | 102.32k | -4.57m | 35.32m | -- | -- | 4.84 | -- | 345.16 | -1.19 | -1.19 | 0.0266 | 1.89 | -- | -- | -- | -- | -- | -- | -- | -- | 71.50 | -- | -4,470.08 | -- | -- | -- | -- | -- | -- | -- | -20.76 | -- | -- | -- |
| Bergenbio ASA | 30.15k | -16.22m | 37.05m | 18.00 | -- | 3.41 | -- | 1,228.90 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
Data as of Apr 19 2024. Currency figures normalised to Herantis Pharma Oyj's reporting currency: Euro EUR
22.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 1.68m | 8.34% |
| Sp-Fund Management Co. Ltd.as of 28 Mar 2024 | 1.11m | 5.48% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 773.50k | 3.84% |
| OP Asset Management Ltd.as of 31 Dec 2023 | 661.50k | 3.28% |
| Nordea Investment Management ABas of 31 Dec 2023 | 347.19k | 1.72% |
| Evli Fund Management Co. Ltd.as of 28 Mar 2024 | 7.12k | 0.04% |
More ▼
Data from 31 Dec 2023 - 28 Mar 2024Source: FactSet Research Systems Inc.
